Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsSmall Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based DesignCrystal structures of novel allosteric peptide inhibitors of HIV integrase identify new interactions at the LEDGF binding siteDevelopment of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutationsCD25 preselective anti-HIV vectors for improved HIV gene therapy.Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravirSolution conformation and dynamics of the HIV-1 integrase core domain.Resistance to integrase inhibitors.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.In vitro evolution of an HIV integrase binding protein from a library of C-terminal domain γS-crystallin variants.Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections.Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designStudy of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Role of raltegravir in HIV-1 management.Using TRIM5α as an HIV therapeutic: the alpha gene?Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.Patterns of resistance development with integrase inhibitors in HIV.HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.Phylogenetic analysis of HIV type 1 CRF02_AG in multiple genes in Italian and African patients living in Italy.Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
P2860
Q24628743-6A564217-2B44-4E71-AAD4-9F9A3D982C77Q27670782-EF455EB3-8EA6-42BA-829B-65609003BEA0Q27671817-08955E3D-D489-41B6-B6DF-3570A2CFC792Q28481393-1D2EC99A-3796-4288-8B28-AB8BFE9D5D8DQ33586299-D505AEFF-431C-4692-9364-1118426EB18CQ33838063-703A0668-C690-4015-A54B-03C75D81D089Q33885382-E4AEACF5-7958-4526-8387-59DD7EFBF01AQ34059896-9CD5E579-6CD3-43B6-96CA-AD05A7F4C737Q34108775-A0B08C2F-C089-4768-A3A0-736493AEB57BQ34363222-8E08ABCC-66C1-4CAB-9D9F-638FD9CB39ECQ34487510-36099559-3921-447E-BE0A-38E974B8D177Q35563298-B071D47F-DD73-4821-8AD1-7383739E37B9Q35694729-32AC07EF-A82A-4C15-9F01-83317B410C8AQ35789343-4F705FC4-74B3-479E-B009-8EE25C12367BQ38002011-1D4C6050-3042-4B3F-8C4A-3B186FA58B33Q38088406-EB4D9AB7-A437-41EC-AE54-658627D3AB94Q39511996-7EF1E547-B8B4-41EB-A9FD-443EEE0001D2Q41760696-3F5A0CE9-2F96-46EA-B9C1-EB2C6CE29251Q41884572-F8B6A9B6-B00B-4F30-A5C8-49B069B148EDQ42094831-C630C92B-FF85-412E-ADF5-B053C40DDEE8Q42214894-D3903076-F052-49B3-BCDC-AED217D07ADDQ42276732-2911BBE4-8A90-465E-9B4F-AA75510CBA9FQ42917410-44112520-8373-4CD0-9CA3-32486E2B1EE5
P2860
Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@en
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@nl
type
label
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@en
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@nl
prefLabel
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@en
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@nl
P2093
P356
P1476
Early emergence of raltegravir ...... eiving HAART salvage regimens.
@en
P2093
Giorgio Barbarini
Micaela Brandolini
Renato Maserati
Roberto Gulminetti
Stefania Paolucci
P304
P356
10.1002/JMV.21651
P577
2010-01-01T00:00:00Z